Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00802919 · ClinicalTrials.gov registry record · Phase 4
Varenicline for Cognitive Deficits and Cigarette Smoking in Schizophrenia - Efficacy and Predictors
A Phase 4 study, sponsored by Nathan Kline Institute for Psychiatric Research.
- Completed
- Registry status
- Phase 4
- Development phase
- 93
- Enrollment target
NCT00802919 is a Phase 4 study that has completed, run by Nathan Kline Institute for Psychiatric Research. The registered enrollment target is 93 participants.
The verdict
NCT00802919, a Phase 4 study, has completed, sponsored by Nathan Kline Institute for Psychiatric Research.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 93 participants
- Enrollment target
Study Summary
This is a 8-week double-blind placebo controlled parallel group study of the efficacy of varenicline (Chantix) for smoking cessation in schizophrenic patients, and its effect on cognitive function in patients with schizophrenia.At some sits evaluation of smoking measures is extended to 12 weeks. Correlations will be made with biological predictors of efficacy: a) measures of nicotinic receptors in lymphocytes b) DNMT1 and GAD67 mRNA in lymphocytes. Subjects will be current cigarette smokers or history of regular smokers.
Interventions
- DRUG Varenicline
- DRUG Placebo for varenicline
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 93 participants |
| Start Date | 2008-09 |
| Est. Completion | 2013-12 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00802919
The ClinicalTrials.gov registry entry for NCT00802919 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 93 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Nathan Kline Institute for Psychiatric Research, which has 20 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Varenicline is the first listed.
NCT00802919 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00802919 about?
NCT00802919 is a clinical study titled "Varenicline for Cognitive Deficits and Cigarette Smoking in Schizophrenia - Efficacy and Predictors". This is a 8-week double-blind placebo controlled parallel group study of the efficacy of varenicline (Chantix) for smoking cessation in schizophrenic patients, and its effect on cognitive function in patients with schizophrenia.At some sits evaluation of smoking measures is extended to 12 weeks. Cor...
What is the current status of trial NCT00802919?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 93 participants. The study started on 2008-09. Estimated completion is 2013-12.
What interventions are being tested in trial NCT00802919?
The interventions under investigation include: Varenicline (DRUG), Placebo for varenicline (DRUG).
Who is sponsoring clinical trial NCT00802919?
This trial is sponsored by Nathan Kline Institute for Psychiatric Research, which has 20 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.